Neuronetics Shares Jump 41% Following Q4 Revenue Surge to $41.8M
Neuronetics reported preliminary Q4 2025 revenue of $41.8 million, up 23% pro forma and 86% year-on-year, with NeuroStar sales of $18.3 million and clinic services of $23.5 million. The company shipped 49 NeuroStar systems, generated $0.9 million in positive operating cash flow and reported $149.2 million in full-year 2025 revenue.
1. Preliminary Q4 Financial Results
Neuronetics posted preliminary Q4 2025 revenue of $41.8 million, marking 23% adjusted pro forma growth and an 86% increase versus Q4 2024. Shares surged 41% in after-hours trading on the strength of these results.
2. Segment Revenue Breakdown
NeuroStar system revenue reached $18.3 million, up 9% pro forma, while clinic services generated $23.5 million, reflecting a 37% pro forma increase over the prior-year quarter.
3. Shipments and Cash Flow
The company shipped 49 NeuroStar Advanced Therapy systems during the quarter and generated $0.9 million in positive operating cash flow, meeting the previously issued guidance range.
4. Full-Year Revenue and Cash Position
Full-year 2025 revenue totaled $149.2 million, up 15% on an adjusted pro forma basis, and the company ended the year with $34.1 million in total cash, including cash equivalents and restricted cash.